198 related articles for article (PubMed ID: 38031361)
41. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.
Kim JY; Nam SJ; Lee JE; Yu J; Chae BJ; Lee SK; Ryu JM; Ahn JS; Im YH; Kim SW; Park YH
Cancer Res Treat; 2022 Oct; 54(4):1091-1098. PubMed ID: 35008143
[TBL] [Abstract][Full Text] [Related]
42. A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer.
Xu D; Wu J; Yu J; Yang Y; Wen X; Yang J; Wei H; Xu X; Li Y; Yang L; Wang L; Wang Y; Ma W; Li N
Front Oncol; 2024; 14():1281643. PubMed ID: 38406813
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.
Huang L; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang HC; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Wang H; Lamour F; Song G; Curran M; Duan C; Lysbet de Haas S; Restuccia E; Shao Z
Nat Commun; 2024 Mar; 15(1):2153. PubMed ID: 38461323
[TBL] [Abstract][Full Text] [Related]
44. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Pandor A; Thokala P; Stevens JW; Kaltenthaler E; Clowes M; Coleman R; Wyld L
Pharmacoeconomics; 2018 Jan; 36(1):29-38. PubMed ID: 28770452
[TBL] [Abstract][Full Text] [Related]
45. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
46. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
[TBL] [Abstract][Full Text] [Related]
47. [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis].
Xin L; Zhang H; Zhang S; Cheng YJ; Liu Q; Xu L; Ye JM; Li T; Duan XN; Liu YH; Li ZH
Zhonghua Wai Ke Za Zhi; 2021 Mar; 59(3):222-227. PubMed ID: 33685057
[No Abstract] [Full Text] [Related]
48. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
Peng DM; Li J; Qiu JX; Zhao L
World J Surg Oncol; 2024 Apr; 22(1):88. PubMed ID: 38582875
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).
Cheng Y; Xiang H; Xin L; Duan X; Liu Y;
Chin Med J (Engl); 2022 Oct; 135(19):2311-2318. PubMed ID: 36535009
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
52. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Spring L; Niemierko A; Haddad S; Yuen M; Comander A; Reynolds K; Shin J; Bahn A; Brachtel E; Specht M; Smith BL; Taghian A; Jimenez R; Peppercorn J; Isakoff SJ; Moy B; Bardia A
Breast Cancer Res Treat; 2018 Dec; 172(3):733-740. PubMed ID: 30220055
[TBL] [Abstract][Full Text] [Related]
55. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA; Martin M; Jung KH; Huang CS; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Fasching PA; Afenjar K; Spera G; Lopez-Valverde V; Song C; Trask P; Boulet T; Sparano JA; Symmans WF; Thompson AM; Slamon D
J Clin Oncol; 2019 Sep; 37(25):2206-2216. PubMed ID: 31157583
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
Canino F; Barbolini M; De Giorgi U; Fontana T; Gaspari V; Gianni C; Gianni L; Maestri A; Minichillo S; Moscetti L; Mura A; Nicoletti SVL; Omarini C; Pagani R; Sarti S; Toss A; Zamagni C; Cuoghi Costantini R; Caggia F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
BMC Cancer; 2024 Jun; 24(1):735. PubMed ID: 38879498
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
[TBL] [Abstract][Full Text] [Related]
59. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
60. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
Front Immunol; 2022; 13():877825. PubMed ID: 35663978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
